Discover the Latest Breakthroughs in Endocrinology at ADA Congress: Learn about the First Oral Non-Peptide GLP-1 Agonist and its Impressive Weight Reduction Results!

2023-06-25 14:19:43

Endocrinology – ADA Congress

Orforglipron, the first oral non-peptide GLP-1 agonist, manages to reduce weight by up to 14.7% without restricting eating and drinking hours.

The new oral GLP-1 agonists would be chronic treatments with a similar safety profile to injectables. Photo: SHUTTERSTOCK
1687722754
#Advances #generation #orals #obesity

Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

Pray for the Recovery of Lebanese Red Cross Secretary-General George Kettaneh

Upheaval in Russia: European Countries on High Alert as Wagner’s Paramilitaries Threaten Putin’s Government

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.